Current Perspectives on the Management of Herpesvirus Infections in Solid Organ Transplant Recipients [PDF]
, 2023 Solid organ transplant recipients (SOTRs) are at high risk of human herpesvirus (HHV)-related morbidity and mortality due to the use of immunosuppressive therapy.
Baan, Carla C. +7 more
core +2 more sources
Immunity Risk Associated With Cytomegalovirus Infection After Organ Transplantation [PDF]
, 2023 Cytomegalovirus (CMV), a member of the Herpesviridae family, is frequently seen in hematopoietic cell transplant (HCT) and solid organ transplant (SOT) patients and is a major cause of morbidity and mortality in absence of antiviral prophylaxis in the ...
Bidisha Ghosh +5 more
core +3 more sources
Autologous adoptive T-cell therapy for recurrent or drug-resistant cytomegalovirus complications in solid organ transplant patients: a single-arm open-label phase I clinical trial [PDF]
, 2018 BACKGROUND: Opportunistic infections including cytomegalovirus (CMV) are a major cause of morbidity and mortality in solid organ transplant (SOT) recipients.
Beagley, Leone +13 more
core +1 more source
A review of Cytomegalovirus (CMV) [PDF]
, 2022 Human cytomegalovirus (CMV) is a ubiquitous virus that has a significant impact on the health of children in Africa and globally. It can be acquired antenatally in utero (cCMV) or postnatally (pCMV) via breastmilk, genital secretions, or blood products ...
Barnabas, Shaun Lawrence +2 more
core +2 more sources
Regulation of the retinoblastoma proteins by the human herpesviruses [PDF]
, 2009 Viruses are obligate intracellular parasites that alter the environment of infected cells in order to replicate more efficiently. One way viruses achieve this is by modulating cell cycle progression.
Kalejta Robert F, Hume Adam J
core +2 more sources
Clinical next-generation sequencing assay combining full-length gene amplification and shotgun sequencing for the detection of CMV drug resistance mutations [PDF]
, 2023 Cytomegalovirus (CMV) causes severe systemic and tissue-invasive disease in immunocompromised patients, particularly solid organ and hematopoietic stem cell transplant recipients.
Caldera, JR +6 more
core +1 more source
Slaying the "Troll of Transplantation"-new frontiers in cytomegalovirus management. A report from the CMV International Symposium 2023 [PDF]
, 2023 : The 2023 International CMV Symposium took place in Barcelona in May 2023. During the 2-day meeting, delegates and faculty discussed the ongoing challenge of managing the risk of cytomegalovirus infection (the Troll of Transplantation) after solid organ
Kotton, Camille N +3 more
core +1 more source
Combinatorial Drug Treatments Reveal Promising Anticytomegaloviral Profiles for Clinically Relevant Pharmaceutical Kinase Inhibitors (PKIs) [PDF]
, 2021 Human cytomegalovirus (HCMV) is a human pathogenic herpesvirus associated with a variety of clinical symptoms. Current antiviral therapy is not always effective, so that improved drug classes and drug-targeting strategies are needed.
Bertzbach, Luca D. +13 more
core +2 more sources
Annals of Internal Medicine: Clinical CasesWe present a case of multidrug-resistant Cytomegalovirus (CMV) and the use of maribavir, a novel oral treatment of resistant CMV, in a nontransplant immunocompromised host. Our patient initially was diagnosed with CMV pharyngitis on biopsy.
Diana Zarowin +6 more
doaj +1 more source
Adoptive Immunotherapy for Prophylaxis and Treatment of Cytomegalovirus Infection
Viruses, 2022 Cytomegalovirus (CMV), a member of the Herpesviridae family, is frequent among hematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients in absence of antiviral prophylaxis, and is a major cause of morbidity and mortality in these ...
Christopher P. Ouellette
doaj +1 more source